RenovaCare has issued a strong rejection to Streetsweeper, known for spreading “short and distort” commentary on companies it targets for short selling, in this case RenovaCare.

"We will not be distracted by the irresponsible and nefarious actions of these short sellers and a handful of internet posters," stated Mr. Thomas Bold, President and CEO of RenovaCare Technologies, Inc. "We have an obligation to expose those who prey on our shareholders for short-term profits and attempt to damage the public trust."

"Meanwhile, our clinical and regulatory teams continue to make incredible strides, with our next major milestone being our initial FDA filing. We are determined to bring our breakthrough stem cell therapy to market with the ongoing strong support of our shareholders.”

To date, over 70 severe burn victims have been treated, with many patients discharged in a matter of days because of their rapid recovery.

The Company’s technologies have been published in numerous prestigious peer-reviewed medical journals; and, RenovaCare has been featured in National Geographic, Bloomberg, Forbes and CNN, and its SkinGun™ is currently on display at the prestigious Science Museum in London. (Click Here To Learn More)

The RenovaCare mission is to build shareholder value by advancing its much-needed technology through the regulatory process and make its products available as quickly as possible to the millions that suffer from burns, chronic and acute wounds and scars, a USD 45 billion market in the U.S. alone.

*RenovaCare products are currently in development. They are not available for sale in the United States. There is no assurance that the company’s planned or filed submissions to the U.S. Food and Drug Administration, if any, will be accepted or cleared by the FDA. – Business Wire